ProCE Banner Activity

Mosunetuzumab SC as First-line Therapy for Patients With High Tumor Burden Follicular Lymphoma: Results of a Phase II Study

Conference Coverage

Mosunetuzumab SC demonstrated high efficacy with no new safety signals in patients with previously untreated, high-burden FL.

Released: December 13, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AbbVie Inc., AstraZeneca, Daiichi Sankyo, Inc., Merck Sharp & Dohme LLC, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc, and Seagen Inc.

AbbVie Inc.


Daiichi Sankyo, Inc.

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Regeneron Pharmaceuticals, Inc

Seagen Inc.